14 Sep 2015 07:00
Akers Biosciences, Inc.
Akers Biosciences Launches METRON® - the First and Only Disposable Breath Ketone Test
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, announces that sales of the Company's consumer-focused METRON® Breath Ketone Test - the first and only disposable breath ketone test - have commenced through the Amazon Marketplace and via the Company's online sales portal www.metron.akersbio.com. This marks the first of a number of channels through which the Company intends to commercialize its transformative line of health and wellness products based on its proprietary MPC® Biosensor technology for evaluating exhaled breath.
The METRON® Breath Ketone Test, part of the Akers Wellness line, is the only disposable breath-based diagnostic device that rapidly determines if the subject is in ketosis. Ketosis is a fat-burning state where the body breaks down body fat for energy. Not only is ketosis a desirable state for the millions of people interested in weight loss, it is also important to fitness enthusiasts as a means of monitoring an efficient metabolism for training and sporting events. Studies have also suggested that it is beneficial for many other health-related concerns.
Ketosis can be affected by several factors, thus it is important to evaluate your ketogenic state regularly if fat loss or a fat burning metabolism is your goal. While there are competitive tests currently available, each has significant drawbacks which hinder their effectiveness. For example, although urinary dipstick ketone tests are inexpensive, the results of these tests are not necessarily related to physiological levels of ketones, and may not even be indicative of the presence or absence of ketosis over time. Additionally, many people may find both the urine and blood testing processes to be unpleasant. In contrast, the METRON® Breath Ketone Test is simple and convenient, and provides accurate analysis of ketones, even over time.
"Quite simply, we believe METRON® is a better way to test for ketosis," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman. "With the METRON® Breath Ketone Test, you no longer need invasive blood draws or inconvenient urine tests - you just breathe into the device and get a highly accurate reading in less than three minutes," continued Dr. Akers. "We think this is going to make a huge difference to people trying to lose weight, those trying to maximize their fitness training, or other people who just want to maintain a healthier body. I'm extremely excited that consumers can now buy this product, and we are proud to provide an innovative solution that can help people live healthier lives," added Dr. Akers.
"METRON® has received a significant amount of interest from consumers, fitness professionals, and health and wellness consultants since we announced our intention to launch the product. In fact, it was the extent of this demand that led us to offer this product through Amazon and our own online sales portal (www.metron.akersbio.com). We've launched initially in America but plan to make METRON® available to consumers worldwide. This launch is a significant event for our company as METRON® forms a cornerstone of our strategy to build shareholder value through our presence in the substantial health and wellness industry," said Dr. Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.
ABOUT AKERS WELLNESS
As big data and personalized health information revolutionize health management, the focus is shifting to prevention - rather than treatment - of disease states. Akers Wellness exists to bring innovative diagnostic tests to market that provide near-instant health information to professionals and consumers so that they can make better decisions to manage health lifestyle choices. Akers Wellness' current portfolio focuses on convenient and easy-to-use breath tests, coupled with mobile technology to enable users to access and track their health information wherever they go!
Akers Wellness brings Innovation for Health…One Breath at a Time.
ABOUT METRON®
The METRON® Breath Ketone Test is a rapid and convenient way to accurately measure ketones to determine if you are in a state of nutritional ketosis, or "fat-burning".
METRON® does not require blood draws or inconvenient urine samples, just your breath! And since breath acetone is highly correlated with the ketones in your blood, the test provides an accurate determination of whether you are in ketosis.
✓ METRON® Breath Ketone Test is the first and only disposable breath test for ketosis
✓ Takes less than 3 minutes!
✓ Highly accurate - correlates well to the benchmark blood-based ketone testing
✓ Facilitates frequent testing to monitor if you are currently in a fat-burning ketogenic state
✓ Results shown with an easy-to-read color change
✓ Uses patented MPC™ Biosensor technology
✓ Small, hand-held disposable design (only 5 1/4" long) - test anywhere!
ABOUT KETOSIS
Ketosis is a metabolic state where the body utilizes fat stores for energy, in contrast to a state of glycolysis, where blood glucose provides energy. Most people in the developed world are regularly in a state of glycolysis.
However, when blood glucose from carbohydrates and simple sugar sources cannot meet cellular energy demands, the body forms ketone bodies from fat tissue and subsequently utilizes these ketone bodies for energy. This is considered being in a ketogenic state or in a state of ketosis, commonly referred to as "fat burning".
Ketosis is a desirable state for many people interested in weight-loss, specifically loss of body fat. Ketosis is also of interest to diabetics for blood sugar control and has shown therapeutic evidence for many other health-related concerns. A ketogenic state can be achieved through dramatically reduced carbohydrate intake and exercise.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com